A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults.
The following regimens will be evaluated in random order in all participants:
A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg)
Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised.
This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

Start Date01 Sep 2025

Sponsor / Collaborator

University of Oxford

NCT06828952

/ Not yet recruitingNot ApplicableIIT

Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis

From this study, it can be concluded that patients who meet the following criteria are more likely to fail expectant management and thus should not be considered for the NOM of uncomplicated acute appendicitis. These include the duration of symptoms before presenting to a surgical emergency , the presence of fever within 24 hours of presenting to a surgical emergency, TLC cells/dL, CRP mg/L, appendix diameter mm, modified Alvarado score , and adult appendicitis score .

Start Date22 Jun 2025

Sponsor / Collaborator

Assiut University

[+1]

NCT06819592

/ Not yet recruitingPhase 3IIT

PRophylaxis Against Early VENTilator-associated Infections to Reduce Mortality in Mechanically Ventilated Intensive Care Unit (ICU) Patients With Acute Brain Injuries: a Phase 3 Randomised, Double Blind, Parallel Group, Placebo-controlled Two-side Superiority Trial

This research is about whether treatment with a commonly used antibiotic can prevent infections in airway and lungs and improves the chance of surviving, if it is given soon after patients commence mechanical ventilation when they have been admitted to hospital with an acute severe brain injury.
An acute severe brain injury can occur as a result of a stroke, a traumatic injury or due to lack of oxygen to the brain that happens as a result of a cardiac arrest.
Patients who are unconscious after an acute severe brain injury often need assistance to breath adequately, and this assistance is given by a breathing tube, connected to a mechanical ventilator. This treatment is an emergency medical treatment. The breathing tube is inserted into the patients' airway by either their mouth or neck. For patients who need assistance with their breathing from a mechanical ventilator, infections in the airways and lungs, known as pneumonia, are a common complication. Everyone naturally has bacteria in their mouth, esophagus and stomach. Clinicians think that during the process of inserting the breathing tube, small amounts of these bacteria can be introduced into the airways and lung when people are unconscious following an acute severe brain injury, or during the process of placing the breathing tube into the airways. These bacteria are now in a place they aren't meant to be and can cause an infections in the airways and lungs known as pneumonia.
The purpose of this research is to see if giving one dose of a common antibiotic can prevent patients developing pneumonia, which is associated with having a breathing tube inserted and being on a ventilator, improving the chance of recovery following the acute severe brain injury and ultimately improving the chance of surviving.
When patients have a known infection, current guidelines are to treat them with antibiotics. Antibiotics work to kill the bacteria causing the infection. When a patient has an infection in their lungs, they often need to stay on the mechanical ventilator for longer. While current practice is to give patients with a proven infection in their airways and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic to patients to prevent these infections before they show signs of pneumonia may lead to better outcomes.

Start Date01 Apr 2025

Sponsor / Collaborator

The George Institute for Global Health

100 Clinical Results associated with Ceftriaxone Sodium

100 Translational Medicine associated with Ceftriaxone Sodium

100 Patents (Medical) associated with Ceftriaxone Sodium

38,221

Literatures (Medical) associated with Ceftriaxone Sodium

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Pharmacist-led antibiotic interventions in infectious disease patients: a Pakistani tertiary care antimicrobial stewardship study

Article

Author: Ur Rehman, Naeem ; Maqbool, Sumeira ; Arif, Mehreen ; Hassan, Ali

BackgroundAntibiotics are widely used medications among infectious disease patients; therefore, proper monitoring and assessment are critical for ensuring rational use. Antimicrobial stewardship addresses the rational and appropriate use of antibiotics, which reinforces overall health outcomes. Ongoing antimicrobial resistance scenarios are an alarming condition for healthcare, necessitating continued practice of such assessments.ObjectivesTo evaluate the use of antibiotics in patients with infectious diseases, implement and evaluate clinical pharmacy interventions that adhere to antimicrobial stewardship protocols.MethodsA before and after study was designed to evaluate clinical pharmacy and antimicrobial stewardship interventions for infectious disease patients at a tertiary care hospital in Lahore. A Performa was designed for manual data collection. Study first identified the signal of error, implemented intervention and noted post-interventional followups.Results102 infectious disease cases were analyzed in total and proposed 136 interventions. Physicians accepted 66% of the interventions (90) and rejected the remaining ones as unjustified. The most accepted intervention was the spectrum-based choice (n = 30), followed by de-escalation of dose (n = 17). Use of ceftriaxone was very high (54 Pt.), followed by vancomycin (30 Pt.).ConclusionAntimicrobial stewardship programmes are critical for any institution's proper health care system. It ensures proper antibiotic outflow to patients, thereby improving their health status. The role of pharmacists in establishing an AMS in a hospital setting is a highly commendable activity that enhances healthcare collaboration and outcomes. Clinical pharmacists should implement such activities to improve patient care.

31 Dec 2025·Emerging Microbes & Infections

Emerging epidemic of the Africa-type plasmid in penicillinase-producing Neisseria gonorrhoeae in Guangdong, China, 2013–2022

Article

Author: Zheng, He-Ping ; Cheng, Kui ; Huang, Jin-Mei ; Wu, Xing-Zhong ; Tang, San-Mei ; Zhang, Zi-Yan ; Qin, Xiao-Lin ; Chen, Wen-Tao ; Chen, Yang ; Xue, Yao-Hua ; Zhou, Han ; Zhan, Qing-Xian ; Lan, Yin-Yuan ; Feng, Zhan-Qin

The prevalence of penicillinase-producing Neisseria gonorrhoeae (PPNG) is a crucial public health concern because of its resistance to penicillin and cephalosporins. From 2013 to 2022, a total of 1748 N. gonorrhoeae isolates from Guangdong, China, were examined for their antibiotic susceptibility and molecular epidemiological characteristics. PPNG prevalence increased markedly from 37.25% to 63.87%. This increase was accompanied by a shift in predominant plasmid types carried by PPNG isolates: the rate of PPNG isolates carrying the Africa-type plasmid increased from 18.42% to 91.55%, whereas the rate of isolates carrying the Asia-type plasmid decreased from 81.58% to 7.58%. The prevalence of bla_TEM-135, which is linked to cephalosporin resistance, declined from 52.63% to 4.37%, whereas that of bla_TEM-1 increased from 47.37% to 86.88%, and new bla_TEM variants emerged (10.99% by 2022). Most bla_TEM-1 (88.26%) and new bla_TEM alleles (83.70%) were associated with the Africa-type plasmid, whereas 86.79% of bla_TEM-135 alleles were linked to the Asia-type plasmid. Resistance to ceftriaxone was higher in the Asia-type group (11.67%) than in the Africa-type, Toronto/Rio-type and non-PPNG groups. Genotyping identified diverse sequence types (STs) among PPNGs, in which MLST ST7363, NG-STAR ST2477, NG-MAST ST17748, and NG STAR CC1124 were predominant. This study underscores the rising prevalence of PPNG in Guangdong driven by clonal expansion and changing plasmid dynamics, affecting cephalosporin resistance and highlighting the need for continued surveillance and research into effective treatment strategies.

31 Dec 2025·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

Author: Guedj, Jeremie ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; de Gunzburg, Jean ; Olivares, Carlos ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

News (Medical) associated with Ceftriaxone Sodium

23 Jan 2025

·www.businesswire.com

binx health and Mass General Hospital Study Shows Significant Positive Impact on Antibiotic Stewardship in Sexual Health

BOSTON--( BUSINESS WIRE )--binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced key findings from a new Massachusetts General Hospital (MGH) study designed to assess the real-world impact of Point of Care (“POC”) testing for Chlamydia trachomatis (“CT”) and Neisseria gonorrhoeae (“NG”) testing in symptomatic patients presenting at a sexual health clinic. The study comes on the heels of The Food and Agriculture Organization of the United Nations (“FAO”), the United Nations Environment Program (“UNEP”), the World Health Organization (“WHO”) and the World Organization for Animal Health (WOAH) welcoming a declaration made at the UN General Assembly meeting, which included the target to reduce human deaths from AMR by 10% by 2030 i . In the USA, antibiotic stewardship has become even more critical since the emergence of new multidrug-resistant gonorrhea strains in Massachusetts in 2023. In response, CDC now recommends the use of high doses of the antibiotic ceftriaxone for treatment ii , making rapid and accurate identification of gonorrhea (NG) even more important to appropriately identify and treat those who are indeed infected and avoiding over treatment in those who are negative. Trials conducted as part of the study focused on comparing the outcomes of POC testing vs Standard of Care (“SOC”) testing as well as key outcomes associated with empiric antibiotic use per patient, time to results, time to etiologic treatment, duration of clinic visit, and implementation potential. The accuracy of binx CT/NG test demonstrated sufficient accuracy to be considered for replacing gram stain SOC testing for both males and females delivering rapid nucleic acid amplification test (NAAT) results 3.75 days faster than the state lab and reduced inappropriate antibiotic treatment by 63%. “Accurate, rapid test results are incredibly helpful for patients and providers,” said Dr. Jana Jarolimova, MD MPH, Infectious Disease Physician, Massachusetts General Hospital. “When clinicians are able to quickly and accurately prescribe treatments in clinic, we can better manage their STIs and ultimately, help patients experience better outcomes.” Today, thirty-five million CT/NG tests are processed annually at central laboratories iii , with most patients leaving the clinic before results are ready. Under this traditional care model, patients who are subsequently determined to be positive for chlamydia or gonorrhea may not return for treatment once they leave the clinic, leading to further infection spread and comorbidities. Findings from the study confirmed that patients want to have their test results before they leave the clinic. 80% of patients acknowledged that they would be willing to wait in clinic for their rapid PCR POC results. Importantly, POC testing can have a dramatic impact on treatment accuracy and improved Healthcare Effectiveness Data and Information Set (“HEDIS”) scores as a standardized measure used to assess the quality of health plans and clinician performance. The 10% improvement observed by MGH for appropriate treatment observed when using the binx CT/NG test over SOC demonstrates positive potential to improve HEDIS scores long term. "Our mission at binx health is to be a key proponent that improves STI care,” said Michael Karsonovich, President of binx health. “The ability to collaborate with Mass General specialist sexual health clinic with this study is a fantastic opportunity to demonstrate how POC testing can truly move the needle in STI diagnosis and treatment. This study allows us to leverage our proprietary technology to identify and assess the benefits of testing and treating in the same visit and the need for transformative technology to help tackle the rise of these infections." About binx health binx health is a healthcare technology and clinical diagnostics company focused on innovating solutions to improve routine testing and convenience, providing timely results to improve patient care. The binx io point-of-care molecular platform is the first ever FDA-cleared, CLIA-waived point-of-care system for the detection of chlamydia and gonorrhea in both males (urine) and females (vaginal swab) that provides central lab performance results in about 30 minutes. The binx io platform is highly flexible, easy to use, and enables rapid testing and treatment in a single patient visit. For more information, visit https://mybinxhealth.com/ i https://www-who-int.libproxy1.nus.edu.sg/news/item/26-09-2024-world-leaders-commit-to-decisive-action-on-antimicrobial-resistance ii https://www-cdc-gov.libproxy1.nus.edu.sg/mmwr/volumes/69/wr/mm6950a6.htm iii Huang W, Gaydos CA et al (2012). Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. Sex Transm Infect. 2013 Mar;89(2):108-14. doi: 10.1136/sextrans-2011-050355. Epub 2012 Sep 14. PMID: 22984085; PMCID: PMC3671871. https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/pmc/articles/PMC3671871/

Clinical Study

15 Jan 2025

·www.prnewswire.com

Visby Medical Secures Additional $3.9M from CARB-X to Fight Antibiotic Resistance with PCR-Based Mutation Detection at the POC

SAN JOSE, Calif., Jan. 15, 2025 /PRNewswire/ -- Visby Medical™, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator ( CARB-X) to accelerate its fight against antibiotic resistance. This funding builds on a $1.2 million grant awarded in December 2023 and propels Visby's development of groundbreaking diagnostic tools that pinpoint resistance-conferring mutations in infections, starting with ciprofloxacin susceptibility. Continue Reading The additional funding will advance Visby's pioneering work funded by CARB-X, which has demonstrated its preliminary ability to detect Neisseria gonorrhoeae (NG) from urine and vaginal swabs and distinguish ciprofloxacin-susceptible strains. Next, Visby will continue development toward integrating these capabilities into its Visby Medical Sexual Health Test, which detects chlamydia, gonorrhea, and trichomoniasis. The company is also developing a digital companion app and AI-driven tools to make result interpretation seamless, while working on cost-cutting innovations for its platform. Latest CARB-X grant propels Visby development of diagnostics to pinpoint resistant mutations in STIs. Post this Ciprofloxacin is a former frontline antibiotic that has been sidelined due to widespread resistance. With Visby's rapid test, doctors could determine if this convenient, inexpensive oral antibiotic is effective and reserve ceftriaxone—currently the only antibiotic that remains effective against resistant gonorrhea—for truly resistant cases. "Antibiotic resistance is a critical concern across all of healthcare, and especially in sexually transmitted infections for which numbers continue to rise," explained Gary Schoolnik, MD, Chief Medical Officer of Visby Medical. "Particularly for N. gonorrhoeae, which is a poster child for acquiring resistance, unlocking the treatment potential of ciprofloxacin could mean the difference between extending the lifetime of ceftriaxone either for decades, or only a handful of years." About Visby Medical Founded in 2012, Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company developed a proprietary technology platform that is the world's first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Their commercialized point-of-care tests for sexually transmitted infections (STIs) and respiratory infections (COVID-19 and the flu) deliver true PCR results in under 30 minutes. For more information, visit . Follow Visby Medical on LinkedIn. CARB-X funding for this research is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views CARB-X or its funders. Media Contact: [email protected] SOURCE Visby Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

14 Jan 2025

·www.businesswire.com

Swiss-based Non-profit GARDP Supports the Development of Debiopharm’s New Potential Treatment for Gonorrhoea

GENEVA & LAUSANNE, Switzerland--( BUSINESS WIRE )--The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae . Multidrug-resistant strains of N. gonorrhoeae have emerged globally, limiting treatment options and elevating this pathogen to the high-priority category on the World Health Organization’s Bacterial Priority Pathogen List. Such pathogens present distinct public health challenges that urgently require new treatments. “Antibiotic-resistant gonorrhoea represents a serious threat to sexual and reproductive health,” said Morgane Vanbiervliet, Manager of Market Intelligence & Business Development, Infectious Diseases, Debiopharm. “Debio 1453 shows encouraging pre-clinical efficacy against resistant strains of N. gonorrhoeae . We are eager to continue to develop this compound in collaboration with GARDP.” Debiopharm has completed the preclinical development of Debio 1453 with ongoing support from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The MOU between Debiopharm and GARDP now sets the stage for a new partnership to develop the compound for regulatory approval and help make the final product available and affordable to treat patients worldwide. “We are very pleased to lay the groundwork for a future partnership with Debiopharm,” said Yann Ferrisse, Director of Business Development at GARDP. “In line with our 2024-2028 strategy, we will continue to identify new opportunities like Debio 1453 to develop and make available treatments for gonorrhoea and other public health threats.” Innovative approaches are necessary to treat N. gonorrhoeae , which has gradually developed resistance to many classes of antibiotics used to treat gonorrhoea infections. A single muscular injection of ceftriaxone is now the last available recommended treatment globally. Recent reports of outbreaks of ceftriaxone-resistant “super gonorrhoea” have heightened the urgency for new antibiotic treatments. Debio 1453 shows promising activity against ceftriaxone-resistant and other multidrug-resistant strains of N. gonorrhoeae . The compound uses a unique and novel mechanism of action to target the FabI enzyme, on which N. gonorrhoeae relies for its growth and survival. In studies thus far, no cross-resistance to any antibiotic class has been observed. With more than 82 million new gonorrhoea infections occurring globally each year, gonorrhoea is the third most common sexually transmitted infection. It can cause serious, lifelong consequences in men and women, and can amplify the spread of HIV in high-prevalence settings. When left untreated in women, gonorrhoea can lead to pelvic inflammatory disease that elevates the risk of complications in pregnancy, including the likelihood of ectopic pregnancies and infertility. Gonorrhoea can also be transmitted during birth to babies, who in turn can have health problems like gonococcal conjunctivitis. Debiopharm Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com We’re on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews GARDP We are a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. We receive vital support from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Bill & Melinda Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. We are GARDP, the Global Antibiotic Research & Development Partnership. www.gardp.org *CARB-X is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. Research reported in this press release is supported by CARB-X. CARB-X funding for this research is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views CARB-X or its funders.

Qualified Infectious Disease ProductMicrobial therapy

100 Deals associated with Ceftriaxone Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D00924	Ceftriaxone Sodium	J01DD04	DB01212

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arthropathy associated with infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Infection of bone	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Lower Respiratory Tract Infections	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Meningitis	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Postoperative infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Sepsis	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Skin and skin structure infections	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Urinary Tract Infections	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Gonorrhea	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Infectious Diseases	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Bacterial Infections	Japan	Taiyo Pharma Co., Ltd.	01 Mar 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ileitis	Discovery	Canada	Theriva Biologics, Inc.	01 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05027516 (ResistAZM, CTgov)	Phase 4	Gonorrhea	42	Rocephin (Rocephine®)	zcrhostjio(vgeqlcaocx) = vdalxbkmxg ejyqodnwhk (dugpbvaptc, vewxfdqzii - uegyqiliog) View more	-	02 Aug 2024
				Azithromycin+Rocephin (Rocephine® + Azithromycin)	twqjdyaukw(sqnykkikop) = pymcfomabf dtcjcljloy (twhldxixit, xjbbgqfrhh - yyaebigkpu) View more
NCT04010539 (EAGLE-1, CTgov)	Phase 3	Gonococcal urethritis	628	Gepotidacin (Gepotidacin)	ykqrknytnk(alvsibtfhv) = vkaniagpkq snechedbzb (nmeglbirbk, rqghfdfwzj - vqfeyvnaqx) View more	-	30 May 2024
				Azithromycin+Ceftriaxone (Ceftriaxone Plus Azithromycin)	ykqrknytnk(alvsibtfhv) = vhtfcswmvs snechedbzb (nmeglbirbk, wnkzafhcat - ykofuzkejq) View more
ATS2024	Not Applicable	Pulmonary Eosinophilia	-	Ceftriaxone	nqnjzjljof(rfpsveoyde) = wwtuzxqhuc ijsustebct (bixxzrjrus ) View more	-	19 May 2024
NCT04010539 (EAGLE-1, NEWS) Manual	Phase 3	Gonorrhea	600	gepotidacin (oral, two doses of 3,000mg)	(ltqtkilxfr) = bmhpnkbgtb ohbybpyhgm (qffapzyijq )	Positive	18 Apr 2024
				intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy	(ltqtkilxfr) = gyhqrnmcdm ohbybpyhgm (qffapzyijq )
AAAAI2024	Not Applicable	Anaphylaxis	-	Cefazolin	lvajbqytzn(nkpuxjfshj) = qsvuzbyexh eclghiferx (msnfubmczi )	-	23 Feb 2024
				Cefoxitin	lvajbqytzn(nkpuxjfshj) = poifqfybpd eclghiferx (msnfubmczi )
NCT02265406 (PROPHY-VAP, Pubmed \| Lancet Respir Med) Manual	Phase 3	Pneumonia, Ventilator-Associated	319	Ceftriaxone 2 g	fnctqselpp(whtoaaydrb) = ioxrroorch tqwhwpqqhz (eemxvaodmg )	Positive	19 Jan 2024
				Placebo	fnctqselpp(whtoaaydrb) = gjibyeugbh tqwhwpqqhz (eemxvaodmg )
NCT05149287 (PROPER, CTgov)	Phase 2	Meniscus disorder \| Inflammation \| Cartilage Injury \| Tibial Meniscus Injuries \| Pain, Postoperative	5	Ceftriaxone (Experimental)	djggxluchk(ikqlbfrlio) = ttvswhbxoh saczmnojcd (ondtronsxg, jibmmrctis - krogylnowd) View more	-	05 Sep 2023
				Placebo (Placebo)	djggxluchk(ikqlbfrlio) = cjgbiryxsl saczmnojcd (ondtronsxg, zkgotacxqe - wgutnprqjy) View more
NCT01265173 (Pubmed \| Am J Gastroenterol)	Not Applicable	Spontaneous bacterial peritonitis First line	261	Cefotaxime	ccqmarxnnx(mqsdyeihbi) = extfuteeja bmnyafzwzy (affwzrssdh )	-	02 Jan 2023
				Ceftriaxone	ccqmarxnnx(mqsdyeihbi) = mtehlycvgr bmnyafzwzy (affwzrssdh )
NCT04218695 (CTgov)	Phase 4	Fibrosis \| Liver Cirrhosis	32	Ceftriaxone (Treatment)	(tqujhpplou) = ywnuzdfsrs eseqgvqhbf (zzlfpfruvr, iepndoganb - mwztteocor) View more	-	31 Aug 2022
				normal saline (Placebo)	(tqujhpplou) = alosjbczwj eseqgvqhbf (zzlfpfruvr, smnlboeyke - uayadvxwes) View more
NCT05216744 (Pubmed \| BMC Infect Dis)	Phase 2	Chlamydia trachomatis infection	125	Ceftriaxone + Doxycycline	ntyclfmsya(npdlyqpmly) = cwbjfazffn zdyjtahsry (chwvgkzasc, 88.8 - 99.1)	Positive	09 Jul 2022
				Cefixime + Doxycycline	ntyclfmsya(npdlyqpmly) = mtghfflvwd zdyjtahsry (chwvgkzasc, 87.1 - 98.4)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis